IDH1 and acute myeloid leukemia: A phase 1b/2 study testing multiple combinations of ivosidenib plus venetoclax in IDH1-mutated AML and myelodysplastic syndrome found CR/CRi rates of 67% to 85% with common adverse events (≥grade 3), including febrile neutropenia (28%) and pneumonia (24%) [131].